A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
Clinical trial NCT05608291 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05608291
- Sponsor
- Regeneron Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-16
- Primary completion
- 2026-07-27
- Enrollment
- 1564
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.